Latest Combination drugs Stories
CHESTNUT RIDGE, N.Y., May 26, 2015 /PRNewswire/ -- Par Specialty Pharmaceuticals, a division of Par Pharmaceutical, Inc., today announced the launch of Cortisporin(®)-TC Otic Suspension
-- New rewards-based program demonstrates Galderma's commitment to aesthetics market with industry-leading benefits for healthcare providers and consumers -- FORT WORTH, Texas, May
SAN DIEGO, May 12, 2015 /PRNewswire/ -- Orexigen Therapeutics, Inc.
- Contrave® net sales total $11.5 million in the first full quarter of launch SAN DIEGO, May 8, 2015 /PRNewswire/ -- Orexigen Therapeutics, Inc.
VP/GM of New Aesthetic & Corrective Business Unit; Senior Director of Organizational Health FORT WORTH, Texas, April 28, 2015 /PRNewswire/ -- Galderma, the company dedicated to skin
NEW YORK, April 15, 2015 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased Orexigen Therapeutics, Inc.
SAN DIEGO, March 30, 2015 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that Tom Cannell has joined as Chief Commercial Officer.
LONDON, March 24, 2015 /PRNewswire/ -- Key Findings--Chronic obstructive pulmonary disorder (COPD) is the third leading cause of death in the United States, and is in fourth
NEW YORK, March 6, 2015 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Orexigen
- The parings of haberdine; also, any kind of fragments.